Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), a biopharmaceutical company based in the U.S., has entered into a license and supply agreement with Japan’s Kissei Pharmaceutical Co., Ltd. The agreement grants Kissei the rights to develop and commercialize Rigel’s Rezlidhia (olutasidenib) across Japan, South Korea, and Taiwan. Rezlidhia is an oral isocitrate dehydrogenase-1 (IDH-1) inhibitor that has been approved in the U.S. for the treatment of IDH-1 mutated acute myeloid leukemia (AML).
As per the terms of the deal, Rigel is set to receive an initial payment of USD 10 million, with the potential for up to USD 152.5 million in additional payments tied to development, regulatory, and commercial milestones. Furthermore, Rigel is eligible to receive product transfer price payments, ranging from the mid-20 to lower-30 percent based on tiered net sales, for the exclusive supply of the drug. Kissei secures exclusive rights to Rezlidhia for AML and all future indications in the specified regions, with initial plans to develop the molecule in Japan for relapsed/refractory (R/R) midostaurin (mIDH1) AML.
This new agreement builds upon an existing partnership between the two companies. In 2018, Kissei licensed from Rigel the rights to develop Tavalisse (fosatamatinib disodium hexahydrate) for chronic immune thrombocytopenia (ITP) and other potential indications in Japan, China, Taiwan, and the Republic of Korea.- Flcube.com
